Huntington Disease, Tardive Dyskinesia
Conditions
Brief summary
This is a single-center, randomized, double-blinded, placebo-controlled, dose escalation trial to evaluate the safety, tolerability and pharmacokinetic of LPM3770164 sustained-release tablets orally administered in healthy subjects under fasting state, providing the rationale information for subsequent clinical trials.
Interventions
LPM3770164 sustained release tablet will be administrated orally single-dose on day 1
LPM3770164 sustained release tablet simulant will be administrated orally single-dose on day 1
Sponsors
Luye Pharma Group Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
1. Subject who voluntarily participate and sign the informed consent form; 2. Healthy male/female volunteers aged 18 to 45 years; 3. Body weight ≥ 50.0 kg for men and ≥ 45.0 kg for women, and body mass index (BMI) 18.5 \ 28.0 kg/m2, inclusive; 4. Able to comply with the lifestyle restrictions.
Exclusion criteria
1. Subject has a history of allergy to any component of the investigational drug or similar drugs, or allergic constitution; 2. Subject has a current or past medical history that may affect the clinical trial or dysfunction, including but not limited to the past or current respiratory system, circulatory system, digestive system, urinary system, reproductive system, nervous system, endocrine system, immune system, motor system, blood system, psychiatry, dermatology and other clinically serious diseases or chronic diseases; or any other diseases that may interfere with the test results; 3. Any surgical condition or condition may significantly affect the absorption, distribution, metabolism and excretion of the drug, or may pose a hazard to the subjects;. 4. Subject has a history of self-mutilation; or at risk of suicide; 5. Subject has a history of surgery within 3 months prior to administration, or failure to recover from surgery, or having an expected surgical plan during the trial; 6. Subject has abnormal vital signs, laboratory abnormalities, and ECGs; 7. Subject has used any of over-the-counter products within 14 days or prescription medications within 28 days prior to dosing; 8. Subject positive for hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV-Ab), HIV antibody (HIV-Ab), or syphilis seroreactivity (Trust); 9. Subject has a history of alcohol abuse within 1 year or positive alcohol breath test results; 10. Subject has a history of substance abuse or a positive urine drug screen; 11. Subject who has daily smoking of ≥ 5 cigarettes; 12. Subject who has consumption of xanthine-rich foods or beverages (such as tea, coffee, cola, or chocolate) within 3 days prior to administration; 13. Subject who has consumption of food or beverages containing grapefruit within 7 days prior to administration; 14. Subject who has participated in other clinical trials within 3 months before administration; 15. Subject has used blood products or being blood donor or blood loss; 16. Pregnant, lactating women, or positive pregnancy test; 17. Subject who refusal to contraception, or plan to donate sperm or ovums; 18. Other conditions which would make participation in the study unsuitable.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Treatment-emergent adverse effects | from baseline to day 28 | Number of participants with treatment-emergent adverse effects will be summarized by Group, System Organ Classification (SOC), Preferred Term (PT), severity and the relationship with treatment. |
Secondary
| Measure | Time frame |
|---|---|
| Abnormal Involuntary Movement Scale (AIMS) | baseline, day 3, day 28 |
| Stanford Sleepiness Scale (SSS) | baseline, day 3, day 28 |
| Blood Pressure | baseline, day 1, day 2, day 3, day 4, day 6, day 8, day 11, day 15, day 28 |
| Pulse Rate | baseline, day 1, day 2, day 3, day 4, day 6, day 8, day 11, day 15, day 28 |
| Physical Examination | baseline, day 15, day 28 |
| 12 lead electrocardiogram corrected QT interval | baseline, day 1, day 2, day 3, day 4, day 6, day 8, day 11, day 15, day 28 |
| Maximum observed concentration (Cmax) | from baseline to day 15 |
| Time to maximum observed concentration (Tmax) | from baseline to day 15 |
| Area under the concentration-time curve (AUC) | from baseline to day 15 |
| Barnes Akathisia Rating Scale (BARS) | baseline, day 3, day 28 |
| Half-life (t1/2) | from baseline to day 15 |
| Mean Residence Time (MRT) | from baseline to day 15 |
| Haematology | baseline, day 3, day 8, day 15, day 28 |
| Blood Chemistry | baseline, day 3, day 8, day 15, day 28 |
| Urinalysis | baseline, day 15, day 28 |
| Coagulation | baseline, day 15, day 28 |
| Body Temperature | baseline, day 1, day 2, day 3, day 4, day 6, day 8, day 11, day 15, day 28 |
| Respiratory Rate | baseline, day 1, day 2, day 3, day 4, day 6, day 8, day 11, day 15, day 28 |
| Simpson-Angus Rating Scale (SAS) | baseline, day 3, day 28 |
| Clearance (CL) | from baseline to day 15 |
Countries
China
Outcome results
None listed